Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 0.03
SHPG's Cash to Debt is ranked lower than
99% of the 831 Companies
in the Global Biotechnology industry.

( Industry Median: 56.93 vs. SHPG: 0.03 )
Ranked among companies with meaningful Cash to Debt only.
SHPG' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 0.03

Equity to Asset 0.51
SHPG's Equity to Asset is ranked lower than
67% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. SHPG: 0.51 )
Ranked among companies with meaningful Equity to Asset only.
SHPG' s 10-Year Equity to Asset Range
Min: 0.25   Max: 0.85
Current: 0.51

0.25
0.85
Interest Coverage 55.13
SHPG's Interest Coverage is ranked lower than
85% of the 380 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SHPG: 55.13 )
Ranked among companies with meaningful Interest Coverage only.
SHPG' s 10-Year Interest Coverage Range
Min: 2.96   Max: 55.13
Current: 55.13

2.96
55.13
F-Score: 5
Z-Score: 4.62
M-Score: -2.90
WACC vs ROIC
10.71%
24.11%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 30.38
SHPG's Operating margin (%) is ranked higher than
92% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: -76.18 vs. SHPG: 30.38 )
Ranked among companies with meaningful Operating margin (%) only.
SHPG' s 10-Year Operating margin (%) Range
Min: -56.61   Max: 35.13
Current: 30.38

-56.61
35.13
Net-margin (%) 58.55
SHPG's Net-margin (%) is ranked higher than
96% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. SHPG: 58.55 )
Ranked among companies with meaningful Net-margin (%) only.
SHPG' s 10-Year Net-margin (%) Range
Min: -59.59   Max: 56.55
Current: 58.55

-59.59
56.55
ROE (%) 50.20
SHPG's ROE (%) is ranked higher than
97% of the 755 Companies
in the Global Biotechnology industry.

( Industry Median: -27.55 vs. SHPG: 50.20 )
Ranked among companies with meaningful ROE (%) only.
SHPG' s 10-Year ROE (%) Range
Min: -90.18   Max: 49.38
Current: 50.2

-90.18
49.38
ROA (%) 27.71
SHPG's ROA (%) is ranked higher than
97% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -23.43 vs. SHPG: 27.71 )
Ranked among companies with meaningful ROA (%) only.
SHPG' s 10-Year ROA (%) Range
Min: -37.5   Max: 31.55
Current: 27.71

-37.5
31.55
ROC (Joel Greenblatt) (%) 160.19
SHPG's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. SHPG: 160.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SHPG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -412.29   Max: 315.7
Current: 160.19

-412.29
315.7
Revenue Growth (3Y)(%) 12.40
SHPG's Revenue Growth (3Y)(%) is ranked higher than
68% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. SHPG: 12.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SHPG' s 10-Year Revenue Growth (3Y)(%) Range
Min: -0.7   Max: 26.8
Current: 12.4

-0.7
26.8
EBITDA Growth (3Y)(%) 38.70
SHPG's EBITDA Growth (3Y)(%) is ranked higher than
88% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. SHPG: 38.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SHPG' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -1.4   Max: 38.7
Current: 38.7

-1.4
38.7
EPS Growth (3Y)(%) 56.30
SHPG's EPS Growth (3Y)(%) is ranked higher than
94% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. SHPG: 56.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SHPG' s 10-Year EPS Growth (3Y)(%) Range
Min: -7   Max: 62.8
Current: 56.3

-7
62.8
» SHPG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

SHPG Guru Trades in Q2 2014

Louis Moore Bacon 5,000 sh (New)
Eric Mindich 251,000 sh (New)
Ken Fisher 4,677 sh (+91.13%)
John Paulson 3,366,539 sh (+33.07%)
Jim Simons 675,575 sh (+20.27%)
Murray Stahl 6,000 sh (unchged)
Andreas Halvorsen Sold Out
Pioneer Investments 36,744 sh (-40.26%)
» More
Q3 2014

SHPG Guru Trades in Q3 2014

Richard Perry 695,800 sh (New)
Paul Singer 107,800 sh (New)
Jeremy Grantham 1,845,359 sh (New)
Daniel Loeb 750,000 sh (New)
David Tepper 185,944 sh (New)
Mario Gabelli 37,850 sh (New)
First Eagle Investment 15,000 sh (New)
Louis Moore Bacon 45,300 sh (+806.00%)
John Paulson 9,046,000 sh (+168.70%)
Murray Stahl 6,000 sh (unchged)
Ken Fisher 2,827 sh (-39.56%)
Jim Simons 320,312 sh (-52.59%)
Eric Mindich 76,781 sh (-69.41%)
» More
Q4 2014

SHPG Guru Trades in Q4 2014

Pioneer Investments 110,458 sh (New)
Andreas Halvorsen 529,784 sh (New)
Leon Cooperman 473,237 sh (New)
First Eagle Investment 82,986 sh (+453.24%)
Ken Fisher 14,594 sh (+416.24%)
Louis Moore Bacon 59,292 sh (+30.89%)
Murray Stahl 6,000 sh (unchged)
Eric Mindich Sold Out
David Tepper Sold Out
Jeremy Grantham Sold Out
Paul Singer Sold Out
Jim Simons Sold Out
Richard Perry Sold Out
John Paulson 8,328,304 sh (-7.93%)
Daniel Loeb 500,000 sh (-33.33%)
Mario Gabelli 16,225 sh (-57.13%)
» More
Q1 2015

SHPG Guru Trades in Q1 2015

Steven Cohen 4,600 sh (New)
Jim Simons 197,512 sh (New)
First Eagle Investment 294,539 sh (+254.93%)
Leon Cooperman 500,192 sh (+5.70%)
Pioneer Investments 116,323 sh (+5.31%)
Ken Fisher 14,791 sh (+1.35%)
Murray Stahl 6,000 sh (unchged)
John Paulson 8,328,304 sh (unchged)
Daniel Loeb Sold Out
Mario Gabelli Sold Out
Andreas Halvorsen Sold Out
Louis Moore Bacon 20,000 sh (-66.27%)
» More
» Details

Insider Trades

Latest Guru Trades with SHPG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Shire PLC

Shire Set To Acquire NPS Pharmaceuticals for $5.2 Billion
Following a number of pharma mergers last year, which included the likes of Actavis and Forest Laboratories, Shire (SHPG) announced on Jan. 11 that it is acquiring NPS Pharmaceuticals (NPSP) for $5.2 billion. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 14.40
SHPG's P/E(ttm) is ranked higher than
86% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 40.20 vs. SHPG: 14.40 )
Ranked among companies with meaningful P/E(ttm) only.
SHPG' s 10-Year P/E(ttm) Range
Min: 12.37   Max: 74.35
Current: 14.4

12.37
74.35
Forward P/E 46.73
SHPG's Forward P/E is ranked higher than
72% of the 311 Companies
in the Global Biotechnology industry.

( Industry Median: 21.05 vs. SHPG: 46.73 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 15.00
SHPG's PE(NRI) is ranked higher than
84% of the 211 Companies
in the Global Biotechnology industry.

( Industry Median: 39.20 vs. SHPG: 15.00 )
Ranked among companies with meaningful PE(NRI) only.
SHPG' s 10-Year PE(NRI) Range
Min: 12.85   Max: 106.92
Current: 15

12.85
106.92
P/B 5.50
SHPG's P/B is ranked lower than
58% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. SHPG: 5.50 )
Ranked among companies with meaningful P/B only.
SHPG' s 10-Year P/B Range
Min: 2.01   Max: 14.23
Current: 5.5

2.01
14.23
P/S 8.30
SHPG's P/S is ranked higher than
62% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 12.17 vs. SHPG: 8.30 )
Ranked among companies with meaningful P/S only.
SHPG' s 10-Year P/S Range
Min: 2.25   Max: 9.28
Current: 8.3

2.25
9.28
PFCF 13.20
SHPG's PFCF is ranked higher than
86% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. SHPG: 13.20 )
Ranked among companies with meaningful PFCF only.
SHPG' s 10-Year PFCF Range
Min: 9.58   Max: 42.14
Current: 13.2

9.58
42.14
POCF 11.42
SHPG's POCF is ranked higher than
85% of the 211 Companies
in the Global Biotechnology industry.

( Industry Median: 31.25 vs. SHPG: 11.42 )
Ranked among companies with meaningful POCF only.
SHPG' s 10-Year POCF Range
Min: 7.59   Max: 26.82
Current: 11.42

7.59
26.82
EV-to-EBIT 29.75
SHPG's EV-to-EBIT is ranked higher than
52% of the 207 Companies
in the Global Biotechnology industry.

( Industry Median: 30.27 vs. SHPG: 29.75 )
Ranked among companies with meaningful EV-to-EBIT only.
SHPG' s 10-Year EV-to-EBIT Range
Min: -14.6   Max: 58.7
Current: 29.75

-14.6
58.7
PEG 0.54
SHPG's PEG is ranked higher than
93% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 2.13 vs. SHPG: 0.54 )
Ranked among companies with meaningful PEG only.
SHPG' s 10-Year PEG Range
Min: 0.58   Max: 1.83
Current: 0.54

0.58
1.83
Shiller P/E 42.80
SHPG's Shiller P/E is ranked higher than
52% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 43.00 vs. SHPG: 42.80 )
Ranked among companies with meaningful Shiller P/E only.
SHPG' s 10-Year Shiller P/E Range
Min: 30.76   Max: 143.7
Current: 42.8

30.76
143.7
Current Ratio 0.52
SHPG's Current Ratio is ranked lower than
93% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. SHPG: 0.52 )
Ranked among companies with meaningful Current Ratio only.
SHPG' s 10-Year Current Ratio Range
Min: 0.52   Max: 7.43
Current: 0.52

0.52
7.43
Quick Ratio 0.40
SHPG's Quick Ratio is ranked lower than
94% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: 4.16 vs. SHPG: 0.40 )
Ranked among companies with meaningful Quick Ratio only.
SHPG' s 10-Year Quick Ratio Range
Min: 0.4   Max: 7.07
Current: 0.4

0.4
7.07
Days Inventory 215.68
SHPG's Days Inventory is ranked lower than
75% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. SHPG: 215.68 )
Ranked among companies with meaningful Days Inventory only.
SHPG' s 10-Year Days Inventory Range
Min: 113.08   Max: 270.35
Current: 215.68

113.08
270.35
Days Sales Outstanding 70.41
SHPG's Days Sales Outstanding is ranked lower than
57% of the 557 Companies
in the Global Biotechnology industry.

( Industry Median: 61.96 vs. SHPG: 70.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
SHPG' s 10-Year Days Sales Outstanding Range
Min: 47.71   Max: 101.67
Current: 70.41

47.71
101.67

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.30
SHPG's Dividend Yield is ranked lower than
90% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 0.87 vs. SHPG: 0.30 )
Ranked among companies with meaningful Dividend Yield only.
SHPG' s 10-Year Dividend Yield Range
Min: 0.16   Max: 0.7
Current: 0.3

0.16
0.7
Dividend Payout 0.04
SHPG's Dividend Payout is ranked higher than
98% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 0.39 vs. SHPG: 0.04 )
Ranked among companies with meaningful Dividend Payout only.
SHPG' s 10-Year Dividend Payout Range
Min: 0.05   Max: 1.23
Current: 0.04

0.05
1.23
Dividend growth (3y) 16.00
SHPG's Dividend growth (3y) is ranked higher than
76% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. SHPG: 16.00 )
Ranked among companies with meaningful Dividend growth (3y) only.
SHPG' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 57.9
Current: 16

0
57.9
Yield on cost (5-Year) 0.64
SHPG's Yield on cost (5-Year) is ranked lower than
77% of the 212 Companies
in the Global Biotechnology industry.

( Industry Median: 1.28 vs. SHPG: 0.64 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SHPG' s 10-Year Yield on cost (5-Year) Range
Min: 0.34   Max: 1.5
Current: 0.64

0.34
1.5
Share Buyback Rate 0.20
SHPG's Share Buyback Rate is ranked higher than
92% of the 483 Companies
in the Global Biotechnology industry.

( Industry Median: -10.70 vs. SHPG: 0.20 )
Ranked among companies with meaningful Share Buyback Rate only.
SHPG' s 10-Year Share Buyback Rate Range
Min: 1.4   Max: -28.8
Current: 0.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 43.10
SHPG's Price/Tangible Book is ranked lower than
107% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: 6.50 vs. SHPG: 43.10 )
Ranked among companies with meaningful Price/Tangible Book only.
SHPG' s 10-Year Price/Tangible Book Range
Min: 2.59   Max: 203.91
Current: 43.1

2.59
203.91
Price/DCF (Projected) 2.00
SHPG's Price/DCF (Projected) is ranked higher than
79% of the 255 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. SHPG: 2.00 )
Ranked among companies with meaningful Price/DCF (Projected) only.
SHPG' s 10-Year Price/DCF (Projected) Range
Min: 1.12   Max: 2.65
Current: 2

1.12
2.65
Price/Median PS Value 2.10
SHPG's Price/Median PS Value is ranked lower than
66% of the 784 Companies
in the Global Biotechnology industry.

( Industry Median: 2.00 vs. SHPG: 2.10 )
Ranked among companies with meaningful Price/Median PS Value only.
SHPG' s 10-Year Price/Median PS Value Range
Min: 0.56   Max: 2.93
Current: 2.1

0.56
2.93
Price/Peter Lynch Fair Value 0.80
SHPG's Price/Peter Lynch Fair Value is ranked higher than
93% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 2.30 vs. SHPG: 0.80 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
SHPG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.6   Max: 2.92
Current: 0.8

0.6
2.92
Price/Graham Number 5.60
SHPG's Price/Graham Number is ranked lower than
64% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. SHPG: 5.60 )
Ranked among companies with meaningful Price/Graham Number only.
SHPG' s 10-Year Price/Graham Number Range
Min: 1.15   Max: 19.65
Current: 5.6

1.15
19.65
Earnings Yield (Greenblatt) 3.40
SHPG's Earnings Yield (Greenblatt) is ranked higher than
89% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. SHPG: 3.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
SHPG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.7   Max: 16
Current: 3.4

1.7
16
Forward Rate of Return (Yacktman) 27.15
SHPG's Forward Rate of Return (Yacktman) is ranked higher than
73% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 14.93 vs. SHPG: 27.15 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) only.
SHPG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.5   Max: 26.3
Current: 27.15

1.5
26.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SHP.UK, SHPGF.USA, S7E.Germany, SP2.Germany, SHPG N.Mexico,
Shire PLC was registered in Jersey on 28th January, 2008. It is a specialty biopharmaceutical company that focuses on developing and marketing specialty medicines that address unmet patient needs. The Company unified its business during 2013 by integrating the operations of the Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT) and Regenerative Medicine (RM) business units into a simplified One Shire organization. The Company has four commercial units that focus exclusively on the commercial execution of its In-Line products in the following specialist therapeutic areas: Rare Diseases, Neuroscience, Gastrointestinal (GI) and Internal Medicine. The clinical development, manufacturing and marketing of the Company's products is subject to governmental regulation in the US, the EU and other territories.
» More Articles for SHPG

Headlines

Articles On GuruFocus.com
8 Top Healthcare Stocks to Watch May 13 2015 
John Paulson's Stocks Trading at Low P/E May 04 2015 
Shire Reports A Good Quarter Promoted By Drug Sales May 03 2015 
Top Stock Picks Among Companies That Recently Increased Dividends Mar 09 2015 
AbbVie To Acquire Biopharmaceutical Firm Pharmacyclics Mar 06 2015 
Valeant Pharmaceuticals Finally Zeros In On Salix Pharmaceuticals Feb 24 2015 
Three Pharma Majors In The Run To Acquire Salix Feb 16 2015 
Pioneer Investments Purchases Time Warner Cable, Kohl's in Q4 Feb 10 2015 
AbbVie’s Q4 Reflects Its Tremendous Growth Potential Going Forward Feb 04 2015 
Shire Set To Acquire NPS Pharmaceuticals for $5.2 Billion Jan 15 2015 

More From Other Websites
These dozen Mass. companies are honed in on drugs for rare diseases (BBJ photo gallery) May 28 2015
SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits May 26 2015
5 Stocks Set To Beat The FTSE 100: Aviva plc, Admiral Group plc, Shire PLC, United Utilities Group... May 26 2015
Block Listing Six Monthly Return May 26 2015
Calls bet on all-time highs in Shire May 26 2015
New Shire research to be presented at World Congress on ADHD highlights treatment portfolio,... May 26 2015
New Shire Research to be Presented at World Congress on ADHD Highlights Treatment Portfolio,... May 26 2015
Can Gilead keep growing without a big deal? May 23 2015
5 Investments That Show John Paulson Knows How to Play M&A May 22 2015
Could M&A Boost Pfizer More? Jefferies Thinks So May 22 2015
All Eyes on Pfizer as Shareholders Await the Mega-Deal: Real M&A May 21 2015
Can video game playing end ADHD drug reliance? May 21 2015
Healthcare Winners and Losers: May 19, 2015 May 19 2015
Shire Has Outperformed AstraZeneca After Acquisition Bids For Both Failed To Materialize May 19 2015
5 Big Pharma Stocks to Trade for Breakout Gains May 19 2015
Circassia £275m fundraising signals revival of UK biotech sector May 19 2015
Synergy Rallies 18% Following News of Paulson & Co. Stake May 18 2015
John Paulson Continues To Bet On Health Care And TV May 17 2015
Shire Recognizes HAE Day with Launch of Interactive Website Calling for Inspirational Wishes May 15 2015
3 Shares Analysts Love: Lloyds Banking Group PLC, Shire PLC And Boohoo.Com PLC May 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK